---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Supportive and symptomatic care"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Supportive and symptomatic care. Topics: Supportive care recommended with multidisciplinary specialist input; Supportive options described in a state Medicaid drug class review; Neurological symptoms: spasticity, cataplexy, and seizures; Swallowing and nutrition: dietary modification and gastrostomy; 3 further topics. 7 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/supportive-and-symptomatic-care"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Supportive and symptomatic care

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Supportive and Symptomatic Care

<a id="topic-2.2.2.1.5-1"></a>

### Supportive care recommended with multidisciplinary specialist input

> “Supportive care to improve quality of life, maximize function, and reduce complications is recommended.”
> “This ideally involves multidisciplinary care by specialists in relevant fields”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.2.1.5-2"></a>

### Supportive options described in a state Medicaid drug class review

> “Most other options are supportive in nature such as mobility aids and rehabilitation for strength and balance, or medications to treat symptoms such as spasticity, hypersalivation, epilepsy, and cataplexy.”
> “Epilepsy should be treated by a specialist as some medications, including carbamazepine and vigabatrin, may aggravate the disease.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-2.2.2.1.5-3"></a>

### Neurological symptoms: spasticity, cataplexy, and seizures

> “Spasticity and spasms should be treated initially by non‐pharmacological means.”
> “If these are unsuccessful, pharmacological agents, including baclofen, tizanidine, benzodiazepines, dantrolene sodium, and botulinum toxin injections, may be considered.”
> “Protriptyline, other tricyclic agents, methylphenidate or modafinil may be efficacious for cataplexy.”
> “Seizures should be treated by a neurologist aware of the disease, considering the possibility of aggravation with some anti‐seizure drugs like carbamazepine and vigabatrin.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.5-4"></a>

### Swallowing and nutrition: dietary modification and gastrostomy

> “Dietary modification and compensatory postures may be beneficial for individuals with dysphagia.”
> “Counseling individuals on the long‐term utility of assisted feeding by gastrostomy tube is recommended early in the disease to prevent delay and improve quality of life.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.5-5"></a>

### Hypersalivation and drooling

> “Patients should be treated with established interventions, including postural drainage ±pharmacological agents such as hyoscine hydrobromide transdermal patches; glycopyrronium bromide orally, subcutaneously or via a gastrostomy and small doses of orally administered atropine, or parotid/submandibular glandular injections of botulinum toxin.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.5-6"></a>

### Hearing impairment: hearing devices

> “When appropriate, patients should be offered hearing devices to improve general communication.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

> “Use of amplification should be guided by clinical needs & recommendations of treating audiologist.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.2.1.5-7"></a>

### Mobility, movement disorders, and sleep

> “Strategies to maintain optimal mobility and reduce falls, such as providing walking/mobility aids, ankle‐foot orthotics, and exercise programs, should be sought proactively to prolong mobility and transfer ability.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

> “A nocturnal sedative may be indicated; melatonin is often effective & well tolerated.”
> “Psychiatric manifestations may be resistant to standard drug therapies.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
